News
Media Coverage

Thursday, November 20, 2014

Ready or Not: Stem Cell Therapies Poised to Enter Trials for Alzheimer’s

https://soulfullsisters.com/programs/help-me-write-my-college-essay/77/ taking viagra on a full stomach buy cialis via paypal buy cialis online per paypal https://ml4t.org/blog/how-to-write-essay-introduction/99/ viagra fast pulse rate thesis statement belonging source link pfizer viagra canada see viagra-like thai pills on the way help with math homework online write a five paragraph essay essay writing on football Uk viagra sales red devil cialis coke vs pepsi essay integumentary assessment hesi case study http://naturesknockout.com/store.php?pill=canada-no-prescription-needed&es=40 viagra abuse effects https://jesuswired.com/writing/coursework-help-uk/12/ follow link source url custom dissertations stupid essay go site go to site i need an essay written for me AlzforumStem cells have been hailed, and hailed some more, as a breakthrough technology. All the same, they have been slow to make real inroads in the understanding and treatment of Alzheimer’s disease. That is about to change, according to scientists who spoke at “Accelerating the Cure for Alzheimer’s Disease through Regenerative Medicine.” READ MORE HERE

Wednesday, August 20, 2014

Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s

Alzheimer's News TodayAn intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies developing stem cell therapies for Alzheimer’s disease and dementia. READ MORE HERE

Stemedica Posts Alzheimer’s Stem Cell Data

BioPortfolio LogoStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE

Stemedica International Posts Alzheimer’s Stem Cell Data

DD&D MagStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE